CO2023015484A2 - Compuesto, composiciones y métodos para el tratamiento de trastornos - Google Patents

Compuesto, composiciones y métodos para el tratamiento de trastornos

Info

Publication number
CO2023015484A2
CO2023015484A2 CONC2023/0015484A CO2023015484A CO2023015484A2 CO 2023015484 A2 CO2023015484 A2 CO 2023015484A2 CO 2023015484 A CO2023015484 A CO 2023015484A CO 2023015484 A2 CO2023015484 A2 CO 2023015484A2
Authority
CO
Colombia
Prior art keywords
methods
compositions
disorders
compound
treatment
Prior art date
Application number
CONC2023/0015484A
Other languages
English (en)
Inventor
Rajiah Aldrin Denny
Yingzhi Bi
Ken Carson
Geraldine Cirillo Harriman
Graham A B Hone
Rajiv Gandhi Govindaraj
David J Diller
Original Assignee
Hotspot Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hotspot Therapeutics Inc filed Critical Hotspot Therapeutics Inc
Publication of CO2023015484A2 publication Critical patent/CO2023015484A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente divulgación incluye, entre otras cosas, compuestos que tratan o disminuyen la gravedad del cáncer, composiciones farmacéuticas y métodos de fabricación y uso de estas.
CONC2023/0015484A 2021-04-16 2023-11-16 Compuesto, composiciones y métodos para el tratamiento de trastornos CO2023015484A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163175974P 2021-04-16 2021-04-16
US202163281493P 2021-11-19 2021-11-19
PCT/US2022/025083 WO2022221704A1 (en) 2021-04-16 2022-04-15 Compounds, compositions and methods of treating cancer

Publications (1)

Publication Number Publication Date
CO2023015484A2 true CO2023015484A2 (es) 2023-11-30

Family

ID=81580947

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0015484A CO2023015484A2 (es) 2021-04-16 2023-11-16 Compuesto, composiciones y métodos para el tratamiento de trastornos

Country Status (14)

Country Link
US (1) US20240228482A1 (es)
EP (1) EP4323358A1 (es)
JP (1) JP2024514339A (es)
KR (1) KR20240037184A (es)
AU (1) AU2022256514A1 (es)
BR (1) BR112023021068A2 (es)
CA (1) CA3215395A1 (es)
CL (1) CL2023003068A1 (es)
CO (1) CO2023015484A2 (es)
IL (1) IL307732A (es)
MX (1) MX2023012245A (es)
PE (1) PE20240767A1 (es)
TW (1) TW202309023A (es)
WO (1) WO2022221704A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118139856A (zh) * 2021-10-29 2024-06-04 海南先声再明医药股份有限公司 作为Cbl-b抑制剂的并环化合物
WO2023205180A1 (en) 2022-04-19 2023-10-26 Nurix Therapeutics, Inc. Biomarkers for cbl, and compositions and methods for their use
US20230414598A1 (en) 2022-06-22 2023-12-28 Nurix Therapeutics, Inc. Combination therapies with cbl-b inhibitor compounds and antiemetic agents
WO2024015863A1 (en) * 2022-07-12 2024-01-18 Hotspot Therapeutics, Inc. Cbl-b inhibitor, compositions comprising a cbl-b inhibitor in a method of treating a disease associated with cell proliferation
WO2024015827A1 (en) * 2022-07-12 2024-01-18 Hotspot Therapeutics, Inc. Solid forms of a triazine derivative as cbl-b modulator
WO2024015864A1 (en) * 2022-07-12 2024-01-18 Hotspot Therapeutics, Inc. Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer
WO2024015861A1 (en) * 2022-07-12 2024-01-18 Hotspot Therapeutics, Inc. Methods of preparation of heterocyclic compounds
WO2024015851A1 (en) * 2022-07-12 2024-01-18 Hotspot Therapeutics, Inc. Treatment of cell proliferation-associated conditions using a combination of a clb-b inhibitor and an additional therapeutic agent
TW202412760A (zh) * 2022-07-18 2024-04-01 香港商英矽智能科技知識產權有限公司 Cbl-b抑制劑及其使用方法
WO2024077244A1 (en) * 2022-10-07 2024-04-11 Hotspot Therapeutics, Inc. Compounds, compositions and methods of treating disorders
WO2024077236A1 (en) * 2022-10-07 2024-04-11 Hotspot Therapeutics, Inc. Compounds, compositions and methods of treating disorders
WO2024086730A1 (en) * 2022-10-19 2024-04-25 Hotspot Therapeutics, Inc. Heterocyclic cbl-b inhibitors for the treatment of cancer
WO2024105563A1 (en) 2022-11-16 2024-05-23 Pfizer Inc. Substituted bicyclic pyridone derivatives
WO2024131939A1 (en) * 2022-12-23 2024-06-27 Insilico Medicine Ip Limited Cbl-b inhibitors and methods of uses thereof
WO2024153240A1 (zh) * 2023-01-19 2024-07-25 珠海宇繁生物科技有限责任公司 一种杂环化合物及其制备方法和应用
WO2024153246A1 (zh) * 2023-01-20 2024-07-25 海南先声再明医药股份有限公司 取代的三环化合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3740837A1 (de) * 1987-11-27 1989-06-08 Schering Ag Substituierte bicyclische triazole, verfahren zu ihrer herstellung und ihre verwendung als herbizide mittel
BRPI0814441A2 (pt) * 2007-07-19 2015-07-14 Schering Corp Compostos de amida heterocíclica como inibidores de proteína cinase
JP5524071B2 (ja) * 2007-10-24 2014-06-18 メルク・シャープ・アンド・ドーム・コーポレーション 複素環フェニルアミドｔ型カルシウムチャネルアンタゴニスト
JP2019535689A (ja) * 2016-10-27 2019-12-12 バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ４，５−縮環１，２，４−トリアゾロン

Also Published As

Publication number Publication date
BR112023021068A2 (pt) 2024-01-23
IL307732A (en) 2023-12-01
US20240228482A1 (en) 2024-07-11
AU2022256514A1 (en) 2023-10-19
CL2023003068A1 (es) 2024-05-03
PE20240767A1 (es) 2024-04-17
EP4323358A1 (en) 2024-02-21
TW202309023A (zh) 2023-03-01
WO2022221704A1 (en) 2022-10-20
KR20240037184A (ko) 2024-03-21
JP2024514339A (ja) 2024-04-01
MX2023012245A (es) 2024-03-11
CA3215395A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
CO2023015484A2 (es) Compuesto, composiciones y métodos para el tratamiento de trastornos
CL2019000221A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
DOP2022000077A (es) Aminas bicíclicas como inhibidoras de la cdk2
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
CL2017002494A1 (es) Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer
UY38476A (es) Inhibidores de arg1 y/o arg2
ECSP20030074A (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
CO2022010330A2 (es) Dosificación de gamma-hidroxibutirato (ghb)
DOP2022000194A (es) Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa
DOP2023000145A (es) Inhibidores de cdk2 y métodos de uso de los mismos
DOP2018000238A (es) Inhibidores del potenciador del homólogo zeste 2
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
CO2022007814A2 (es) Ligandos de la pseudoquinasa tyk2
AR119681A1 (es) Métodos de tratamiento del cáncer de mama con tucatinib
CL2019002583A1 (es) Inhibidores duales de magl y faah.
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
CL2022002589A1 (es) Tratamiento de trastornos respiratorios
CO2022014499A2 (es) Moduladores de nlrp3
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
CL2019001618A1 (es) Uso de compuestos de carbamato para prevención, alivio o tratamiento del trastorno bipolar.
CL2020002347A1 (es) Nuevo compuesto y composición farmacéutica que lo comprende
CL2022003206A1 (es) Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501)
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
CL2021001944A1 (es) Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias
BR112022024988A2 (pt) Compostos e métodos para tratamento de infecções fúngicas